Inogen (NASDAQ:INGN) Earns Buy Rating from Analysts at B. Riley

B. Riley initiated coverage on shares of Inogen (NASDAQ:INGN - Free Report) in a research report report published on Sunday, MarketBeat Ratings reports. The firm issued a buy rating and a $14.00 price target on the medical technology company's stock. B. Riley also issued estimates for Inogen's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective on the stock in a research note on Thursday, May 22nd. Stifel Nicolaus cut their price target on Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen cut Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.

Inogen Stock Up 0.6%

INGN stock traded up $0.04 during trading on Friday, hitting $6.64. The company had a trading volume of 342,887 shares, compared to its average volume of 242,009. The firm has a 50-day moving average price of $6.63 and a 200-day moving average price of $8.24. Inogen has a 12 month low of $5.70 and a 12 month high of $13.33. The stock has a market cap of $178.55 million, a price-to-earnings ratio of -5.77 and a beta of 1.64.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The firm had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. Equities analysts expect that Inogen will post -1.73 EPS for the current year.

Institutional Trading of Inogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. AlphaQuest LLC bought a new position in Inogen in the fourth quarter valued at approximately $43,000. GAMMA Investing LLC boosted its holdings in shares of Inogen by 5,738.9% in the 1st quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock valued at $400,000 after buying an additional 5,452 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Inogen in the 4th quarter valued at approximately $56,000. Integrated Quantitative Investments LLC bought a new position in shares of Inogen in the 4th quarter valued at about $92,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $94,000. Institutional investors own 89.94% of the company's stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.